Skip to main content

Advertisement

SpringerLink
Log in

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU)

  • Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Once metastatic bladder cancer has progressed to first-line treatment, the number of therapeutic options is scarce. Among chemotherapeutic agents showing activity in phase II trials, including taxanes, vinflunine (VFL) is the only one shown to increase overall survival in a phase III trial. In addition to its efficacy, VFL is safe in special population groups. Despite this, the prognosis for these patients remains poor, and more effective therapies need to be developed. Agents acting on new therapeutic targets as well as biomarkers to aid matching patients to specific treatments are currently under evaluation. In this regard, immunotherapy is showing promising results. In this article, a critical review of current treatments and future prospects is made, and therapy recommendations are made based on existing scientific evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.

    Article  CAS  PubMed  Google Scholar 

  2. Kogevinas M, Mannetje AT, Cordier S, Ranft U, González CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control. 2003;14(10):907–14.

    Article  PubMed  Google Scholar 

  3. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J. 2009;3(6-S4):193–8.

    Article  Google Scholar 

  4. Blick C, Hall P, Pwint T, Al‐Terkait F, Crew J, Powles T, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle‐invasive transitional cell carcinoma of the bladder. Cancer. 2012;118(16):3920–7.

    Article  CAS  PubMed  Google Scholar 

  5. Sternberg C, De Mulder P, Schornagel J, Theodore C, Fossa S, Van Oosterom A, et al. Randomized phase III trial of high–dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol. 2001;19(10):2638–46.

    CAS  PubMed  Google Scholar 

  6. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.

    Article  CAS  PubMed  Google Scholar 

  7. Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066–73.

    PubMed  Google Scholar 

  8. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Dogliotti L, Cartenì G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–41.

    Article  CAS  PubMed  Google Scholar 

  10. Bennouna J, Fumoleau P, Armand J-P, Raymond E, Campone M, Delgado F-M, et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol. 2003;14(4):630–7.

    Article  CAS  PubMed  Google Scholar 

  11. Johnson P, Geldart T, Fumoleau P, Pinel M-C, Nguyen L, Judson I. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs. 2006;24(3):223–31.

    Article  CAS  PubMed  Google Scholar 

  12. Zhao X-P, Zhong J, Liu X-Q, Wang G-J. CYP3A4 mediated in vitro metabolism of vinflunine in human liver microsomes. Acta Pharmacol Sin. 2007;28(1):118–24.

    Article  CAS  PubMed  Google Scholar 

  13. Focan C, Van Heugen J, Kreutz F, Leroy I, De Graeve J, Blanchot G et al., editors. Vinflunine metabolism and disposition in cancer patients. Proc Am Soc Clin Oncol; 2002. p. 124a (Abstract 495).

  14. Aparicio LMA, Pulido EG, Gallego GA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs. 2012;23(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  15. Aparicio LA, Castosa R, Haz-Conde M, Rodríguez M, Blanco M, Valladares M, et al. Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells. BMC Cancer. 2014;14(1):507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kruczynski A, Barret J-M, Etiévant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998;55(5):635–48.

    Article  CAS  PubMed  Google Scholar 

  17. Ngan VK, Bellman K, Panda D, Hill BT, Jordan MA, Wilson L. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. 2000;60(18):5045–51.

    CAS  PubMed  Google Scholar 

  18. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42(16):2821–32.

    Article  CAS  PubMed  Google Scholar 

  19. Holwell S, Hill B, Bibby M. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001;84(2):290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997;15(5):1853–7.

    CAS  PubMed  Google Scholar 

  21. Papamichael D, Gallagher C, Oliver R, Johnson P, Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer. 1997;75(4):606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol. 2002;20(4):937–40.

    Article  CAS  PubMed  Google Scholar 

  23. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24(21):3451–7.

    Article  CAS  PubMed  Google Scholar 

  24. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25(3):265–70.

    Article  CAS  PubMed  Google Scholar 

  25. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11(9):861–70.

    Article  CAS  PubMed  Google Scholar 

  26. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer. 2006;94(10):1395–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, et al. Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma. Cancer. 2009;115(18):4110–7.

    Article  CAS  PubMed  Google Scholar 

  28. Bellmunt J, Théodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454–61.

    Article  CAS  PubMed  Google Scholar 

  29. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.

    CAS  PubMed  Google Scholar 

  30. • Bellmunt J, Fougeray R, Rosenberg J, Von der Maase H, Schutz F, Salhi Y, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013;24(6):1466–72. The updated OS data confirm the positive treatment effect of vinflunine on survival that was previously reported.

    Article  CAS  PubMed  Google Scholar 

  31. Culine S, Lucas C, Salhi Y, Bellmunt J. Updated survival results of the phase III trial comparing vinflunine (V) to best supportive care (BSC) in advanced transitional cell carcinoma of the urothelium (TCC) after failure of a prior platinum-containing regimen. Eur Urol Suppl. 2010;9(2):38.

    Article  Google Scholar 

  32. Tourani J, Mourey L, Servent V, Nguyen T, Ravaud A, Girre V, et al. Influence of age on the pharmacokinetics of iv vinflunine: results of a phase I trial in elderly cancer patients. J Geriatr Oncol. 2012;3(1):41–8.

    Article  Google Scholar 

  33. Medioni J, Guillot A, Spaeth D, Di Palma M, Theodore C. Historical data in real life from patients treated by vinflunine for an advanced or metastatic urothelial carcinoma: results of the CURVE study. BMC Cancer. 2016;16(1):217.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Hegele A, Goebell P, Matz U, Neuhaus T. Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data. Urol Int. 2013;92(2):174–9.

    Article  CAS  PubMed  Google Scholar 

  35. Castellano D, Puente J, de Velasco G, Chirivella I, López-Criado P, Mohedano N, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14(1):1.

    Article  CAS  Google Scholar 

  36. Isambert N, Delord JP, Tourani JM, Fumoleau P, Ravaud A, Pinel MC, et al. How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. Br J Clin Pharmacol. 2014;77(3):498–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Delord J, Ravaud A, Bennouna J, Fumoleau P, Favrel S, Pinel M, et al. Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Invest New Drugs. 2013;31(3):724–33.

    Article  CAS  PubMed  Google Scholar 

  38. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5.

    Article  PubMed  Google Scholar 

  39. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, et al. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013;63(4):717–23.

    Article  PubMed  Google Scholar 

  40. Harshman L, Fougeray R, Choueiri T, Schutz F, Salhi Y, Rosenberg J, et al. The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer. 2013;109(10):2548–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Pond G, Bellmunt J, Rosenberg J, Bajorin D, Regazzi A, Choueiri T, et al. Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. Clin Genitourin Cancer. 2015;13(1):71–9.

    Article  CAS  PubMed  Google Scholar 

  42. Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, et al. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer. 2015;13(2):185–92.

    Article  PubMed  Google Scholar 

  43. Krajewski KM, Fougeray R, Bellmunt J, Pons F, Schutz FA, Rosenberg JE, et al. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012;48(10):1495–502.

    Article  CAS  PubMed  Google Scholar 

  44. Kitamura H, Taguchi K, Kunishima Y, Yanase M, Takahashi A, Shigyo M, et al. Paclitaxel, ifosfamide, and nedaplatin as second‐line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group. Cancer Sci. 2011;102(6):1171–5.

    Article  CAS  PubMed  Google Scholar 

  45. Han K, Joung J, Kim T, Jeong I, Seo H, Chung J, et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer. 2008;98(1):86–90.

    Article  CAS  PubMed  Google Scholar 

  46. Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol. 2007;52(4):1115–22.

    Article  CAS  PubMed  Google Scholar 

  47. Srinivas S, Harshman LC. A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Chemotherapy. 2009;55(5):321–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Joung JY, Kwon WA, Cho IC, Kim EK, Park S, Yoon H, et al. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum‐based regimens. Int J Urol. 2011;18(5):350–7.

    Article  CAS  PubMed  Google Scholar 

  49. Edeline J, Loriot Y, Culine S, Massard C, Albiges L, Blesius A, et al. Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum–gemcitabine regimen. Eur J Cancer. 2012;48(8):1141–6.

    Article  CAS  PubMed  Google Scholar 

  50. Joly F, Houédé N, Noal S, Chevreau C, Priou F, Chinet-Charrot P, et al. Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer. 2009;7(2):E28–33.

    Article  CAS  PubMed  Google Scholar 

  51. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy. Cancer. 2001;92(12):2993–299.

    Article  CAS  PubMed  Google Scholar 

  52. Kanai K, Kikuchi E, Ohigashi T, Miyajima A, Nakagawa K, Nakashima J, et al. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy. Int J Clin Oncol. 2008;13(6):510–4.

    Article  CAS  PubMed  Google Scholar 

  53. Fechner G, Siener R, Reimann M, Kobalz L, Albers P. Randomised phase II trial of gemcitabine and paclitaxel second‐line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60(1):27–31.

    Article  CAS  PubMed  Google Scholar 

  54. Albers P, Park S-I, Niegisch G, Fechner G, Steiner U, Lehmann J, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22(2):288–94.

    Article  CAS  PubMed  Google Scholar 

  55. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Evan YY, Quinn DI, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30(5):507–12.

    Article  CAS  PubMed  Google Scholar 

  56. Ko Y-J, Canil CM, Mukherjee SD, Winquist E, Elser C, Eisen A, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013;14(8):769–76.

    Article  CAS  PubMed  Google Scholar 

  57. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol. 1997;15(2):589–93.

    CAS  PubMed  Google Scholar 

  58. Lorusso V, Pollera C, Antimi M, Luporini G, Gridelli C, Frassineti G, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer. 1998;34(8):1208–12.

    Article  CAS  PubMed  Google Scholar 

  59. Gebbia V, Testa A, Borsellino N, Mauceri G, Varvara F, Tirrito M, et al. Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter. 1998;150(1):11–5.

    Google Scholar 

  60. Albers P, Siener R, Härtlein M, Fallahi M, Haeutle D, Perabo F, et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie. 2002;25(1):47–52.

    CAS  PubMed  Google Scholar 

  61. Akaza H, Naito S, Usami M, Miki T, Miyanaga N, Taniai H. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol. 2007;37(3):201–6.

    Article  PubMed  Google Scholar 

  62. Benjamin DJ, Bambury RM, Chaim J, Zabor EC, Ostrovnaya I, Garcia-Grossman IR, et al. Efficacy of single-agent pemetrexed in platinum refractory metastatic urothelial cancer (mUC). ASCO Annu Meet Proc. 2014;32(4 suppl):322.

    Google Scholar 

  63. •• Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. In this study, three molecular subtypes of MIBC are identified and these have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci. 2014;111(8):3110–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Network CGAR. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.

    Article  CAS  Google Scholar 

  66. Guancial EA, Rosenberg JE. The role of genomics in the management of advanced bladder cancer. Curr Treat Options Oncol. 2015;16(1):1–15.

    Article  Google Scholar 

  67. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015;41(2):170–8.

    Article  CAS  PubMed  Google Scholar 

  68. Moon DG, Lee SE, Oh MM, Lee SC, Jeong SJ, Hong SK, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol. 2014;45(3):1027–35.

    CAS  PubMed Central  Google Scholar 

  69. Milowsky MI, Iyer G, Regazzi AM, Al‐Ahmadie H, Gerst SR, Ostrovnaya I, et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int. 2013;112(4):462–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, Knowles MA. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 2009;15(19):6008–17.

    Article  CAS  PubMed  Google Scholar 

  71. García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res. 2012;18(9):2603–12.

    Article  CAS  PubMed  Google Scholar 

  72. Wong Y-N, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(28):3545–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Petrylak DP, Tangen CM, Van Veldhuizen PJ, Goodwin JW, Twardowski PW, Atkins JN, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105(3):317–21.

    Article  CAS  PubMed  Google Scholar 

  74. Wülfing C, Machiels JPH, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115(13):2881–90.

    Article  CAS  PubMed  Google Scholar 

  75. Culine S, Sellam Z, Bouaita L, Assaf E, Delbaldo C, Verlinde-Carvalho M, et al. Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series. Anticancer Res. 2012;32(9):3949–52.

    CAS  PubMed  Google Scholar 

  76. Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25(16):2218–24.

    Article  CAS  PubMed  Google Scholar 

  77. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer. Cancer. 2009;115(18):4090–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28(8):1373–9.

    Article  CAS  PubMed  Google Scholar 

  79. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancer Oncol. 2012;13(8):810–6.

    Article  CAS  Google Scholar 

  80. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923–6.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Acquaviva J, He S, Zhang C, Jimenez J-P, Nagai M, Sang J, et al. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism. Mol Cancer Res. 2014;12(7):1042–54.

    Article  CAS  PubMed  Google Scholar 

  82. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.

    Article  CAS  PubMed  Google Scholar 

  83. •• Rosemberg JE, Hoffman-Censits C, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial. Lancet. 2016;387:1909–20. Atezolizumab showed durable activity and good tolerability in patients with advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy. This study show the association of TCGA subtypes with response to immune checkpoint inhibition.

    Article  CAS  Google Scholar 

  84. Plimack ER, Bellmunt J, Gupta S, Berger R, Montgomery RB, Heath K et al., editors. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. ASCO Annual Meeting Proceedings; 2015.

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Santiago University Hospital, Santiago, Spain

    Jorge García & Urbano Anido

  2. Department of Oncology, POVISA Hospital, Vigo, Spain

    Lucia Santomé

  3. Department of Oncology, Ourense University Hospital, Ourense, Spain

    Ovidio Fernández-Calvo

  4. Department of Oncology, Ferrol University Hospital, Ferrol, Spain

    Javier Afonso-Afonso

  5. Department of Oncology, Álvaro Cunqueiro Hospital, Vigo, Spain

    Martín Lázaro

  6. Department of Oncology, Galicia Oncology Center, A Coruña, Spain

    Ana Medina

  7. Department of Oncology, Lucus Augusti University Hospital, Lugo, Spain

    Sergio Vázquez Estévez

Authors
  1. Jorge García
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lucia Santomé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Urbano Anido
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ovidio Fernández-Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Javier Afonso-Afonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martín Lázaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana Medina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sergio Vázquez Estévez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Vázquez Estévez.

Ethics declarations

Conflict of Interest

Jorge García declares that he has no conflict of interest.

Lucia Santomé declares that she has no conflict of interest.

Urbano Anido has received compensation from Novartis, Pfizer, Sanofi, Pierre Fabre, Janssen, Bayer, and Astellas for the provision of expert testimony, and has received reimbursement for travel expenses from Astellas, Bayer, and Pfizer.

Ovidio Fernández-Calvo declares that he has no conflict of interest.

Javier Afonso-Afonso declares that he has no conflict of interest.

Martín Lázaro declares that he has no conflict of interest.

Ana Medina declares that she has no conflict of interest.

Sergio Vázquez declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

García, J., Santomé, L., Anido, U. et al. Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). Curr Oncol Rep 18, 72 (2016). https://doi.org/10.1007/s11912-016-0556-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-016-0556-3

Keywords

Search

Navigation